The Latest: FDA considers boosters of Moderna, J&J vaccines
NEW YORK — Many Americans who got Pfizer vaccinations are rolling up their sleeves for a booster shot. Meanwhile, millions who received the Moderna or Johnson & Johnson vaccine wait to learn when it’s their turn.
Federal regulators begin tackling that question this week. On Thursday and Friday, the Food and Drug Administration convenes its independent advisers for the first stage in the process of deciding whether extra shots of the two vaccines should be dispensed and, if so, who should get them and when.
The final go-ahead is not expected for at least another week. After the FDA advisers give their recommendation, the agency will make an official decision on whether to authorize boosters. Then a panel convened by the Centers for Disease Control and Prevention will offer more specifics on who should get them.
The FDA meetings come as U.S. vaccinations have climbed back above 1 million per day on average, an increase of more than 50% over the past two weeks. The rise has been driven mainly by Pfizer boosters and employer vaccine mandates.